Thursday, December 25, 2025 12/25/2025

Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder

Award Number: R43DA060646
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2026

Group Awards By:

View Award Description

Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder - PROJECT SUMMARY Fannin Partners is developing a drug, 11h, for the management of stimulant use disorders (StUD), an area of major unmet medical need. Our key innovation is selective inhibition of a key inflammatory pathway in the brain while reducing the adverse events associated with currently available non-selective inhibitors. StUDs have increased rapidly in the last decade with stimulants now the 2nd most commonly used illicit substance (after cannabis products), related to 75% of federal drug-related offenses. Methamphetamine (MA) is a stimulant with high abuse potential and has become one of the most widely available and illicitly-used substances. Despite the lack of specific therapeutics approved for StUD, inpatient treatment costs are estimated at ~$2.15 billion. Thus, new treatment options are urgently needed - ideally orally available and with new mechanisms. 11h is orally bioavailable and shows promising efficacy in multiple animal models of substance use disorders, including with cocaine, as well as anti-inflammatory activity. 11h appeared well tolerated in a variety of toxicology models. 11h also demonstrated a favorable pharmacokinetic profile in animals with oral bioavailability and strong brain penetration. Here, we propose to further develop the drug through early pre-IND efficacy and toxicology studies. Our experienced management team and key collaborators provide the environments required to successfully achieve our proposed aims. We truly believe that this novel drug could potentially play a crucial role in saving lives and reducing the current health crisis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	FANNIN PARTNERS LLC	3900 ESSEX LN	HOUSTON	TX	77027	HARRIS	USA	Drug Use and Addiction Research Programs	000	1	3/12/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $320,000 )
2024	2024	FANNIN PARTNERS LLC	3900 ESSEX LN	HOUSTON	TX	77027	HARRIS	USA	Drug Use and Addiction Research Programs	000	1	4/19/2024	NEW	$320,000
														Subtotal = $320,000

Grand Total All Awards = $320,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder

Award Number: R43DA060646

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer